Ct103a
WebFeb 21, 2024 · The FDA has granted an orphan drug designation to the investigational anti-BCMA CAR T-cell therapy CT103A for use as a potential therapeutic option in patients relapsed/refractory multiple myeloma. WebJan 4, 2024 · To evaluate the safety and efficacy of the CT103A, a self-developed BCMA-targeting CAR construct against BCMA, in patients with AQP4-IgG seropositive NMOSD, an ongoing, investigator-initiated, open-label, single-arm, phase 1 clinical trial is conducted at our center. In total, 12 patients were administered with a CAR-BCMA infusion.
Ct103a
Did you know?
WebIASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-T WebMar 30, 2024 · 南京传奇：JNJ-4528. JNJ-4528是南京传奇与杨森公司联合开发的一款靶向BCMA的CAR-T疗法，这是一种结构性分化的CAR-T, 具有两个靶向BCMA的单结构域抗体。. 在中国，JNJ-4528已被NMPA纳入突破性治疗品种。. 在美国，FDA也已授予其突破性疗法认定。. 2024年12月，杨森公司和 ...
WebJan 6, 2024 · CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells … WebDec 22, 2024 · About CT103A. Equecabtagene autoleucel (CT103A) is a BCMA chimeric antigen receptor autologous T cell injection, a lentiviral vector containing a CAR structure …
WebNov 13, 2024 · The circulating CT103A cells were detected in the blood by flow and digital polymerase chain reaction, peaking at 14 days (ranging from 9 to 25), and remaining detectable in 12/16 patients, at the time of their last evaluation. Patient #1 (the first patient treated) has now exceeded 314 days of CART persistence, post-infusion. WebDec 20, 2024 · December 20, 2024. In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy, led to rapid and durable responses in patients with heavily pretreated relapsed/refractory multiple myeloma. These outcomes were seen even among patients …
http://www.cnzhilian.com/jiankang/2024-03-28/577811.html
WebJan 21, 2024 · In this study, CT103A will be infused at the dose of 1.0×10^6 cells/Kg, while Selinexor was set as two dosage groups of 20 mg/week and 40 mg/week. Subjects in all … ear to elbowCT103A is a fully human anti-BCMA CAR engineered T cell which overcomes this big hurdle and thus induces and potentially sustains complete remissions. However, there still remain other challenges of CAR-T cells in MM, including T cell- and tumor-related challenges, including the underlying health status of the immune compartment and the immune ... ear to ear youtubeWebOct 2, 2024 · CT103A is an innovative therapy co-developed by IASO BIO and Innovent Biologics, Inc. Previous studies indicated patients with relapsed/refractory multiple … ct sddWebApr 27, 2024 · 1 Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. 2 Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. PMID: 35402835. PMCID: PMC8975015. DOI: … eartoguard.usWebFeb 21, 2024 · Ascending doses of CT103A were investigated in an open-label Phase 1 clinical trial (ChiCTR1800018137) that involved 18 relapsed or refractory multiple myeloma patients who had a median of four prior therapy lines.After a median of 394 days (a little over one year), all had responded to the treatment, with 72.2% achieving complete responses … ear to ground meaningWebCT103A is safe, highly productive, and long persistent in RRMM patients and can be developed as a promising therapy for RRMM. Patients who relapsed from prior non-human BCMA CAR T-cell therapy could still benefit from CT103A. This approach is being explored in the phase Ⅱ study. Keyword(s): CAR-T, Multiple myeloma, Phase I cts dartmouthWebDec 24, 2024 · Patients received the recommended phase 2 dose of CT103A (1.0 x 10 6 cells/kg) after lymphodepletion with fludarabine and cyclophosphamide. For the entire … cts dartmouth ns